News & Updates
Filter by Specialty:

Adjuvant palbociclib + ET does not improve outcomes vs ET alone in early breast cancer
Adjuvant palbociclib in combination with endocrine therapy (ET) does not improve invasive disease-free survival (iDFS) or secondary endpoints vs ET alone in patients with hormone receptor–positive, HER2-negative early breast cancer, final results of the phase III PALLAS trial have shown.
Adjuvant palbociclib + ET does not improve outcomes vs ET alone in early breast cancer
15 Dec 2021
DOACs tied to lower risk of delayed ICH than older blood thinning meds
Patients on older antiplatelet or anticoagulant agents who sustain head trauma may be at an increased risk of delayed post-traumatic intracranial haemorrhage (ICH) than those on direct oral anticoagulants (DOACs), according to a retrospective study presented at RSNA 2021.
DOACs tied to lower risk of delayed ICH than older blood thinning meds
14 Dec 2021
Shorter flare duration best indicator of treatment success in gout
Patients with gout consider flare duration, flare frequency, and pain severity when thinking about treatment efficacy over time, according to a study. Of these factors, shorter flare duration is deemed to be the most common indicator of successful treatment.
Shorter flare duration best indicator of treatment success in gout
14 Dec 2021
App-delivered mindfulness training eases anxiety
Mindfulness training (MT) delivered through an app (Unwinding Anxiety) significantly alleviates anxiety, a study has shown. Increases in psychological nonreactivity and reductions in worry mediate the effects of this app, which suggests a specific targeting of reinforcement learning.
App-delivered mindfulness training eases anxiety
14 Dec 2021
Antidepressant therapy: To continue or not?
In individuals who had been on antidepressant therapy for at least 9 months but felt well enough to consider discontinuing, the risk of relapse of depression was greater among those who stopped vs those who carried on with their current regimen, the ANTLER* trial has shown.